Oppenheimer analyst Jay Olson raised the firm’s price target on Revolution Medicines (RVMD) to $150 from $75 and keeps an Outperform rating on the shares. The firm notes Revolution has been the subject of substantial M&A speculation entering 2026 as it sees multiple milestones this year that could sweeten a potential deal. Oppenheimer’s biotech M&A analysis shows increasing strategic demand for novel approaches to areas of high unmet need while oncology remains dominant, supporting Oppenheimer as an attractive potential takeout candidate.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines: Differentiated RAS(ON) Pipeline Underpins Overweight/Buy Rating and $92 December 2026 Target
- Revolution Medicines falls -17.1%
- Revolution Medicines Advances RMC-5127 KRAS Program, Extending Its Oncology Reach
- Revolution Medicines falls -19.7%
- Morning Movers: USA Rare Earth surges after government funding pact